Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 8: | Line 8: | ||
*CK7 +ve. | *CK7 +ve. | ||
*TTF-1 -ve. | *TTF-1 -ve. | ||
*HepPar-1 +ve. | *HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).<ref name=pmid28555282/> | ||
*SMARCA4 -ve. | *SMARCA4 -ve. | ||
Revision as of 22:16, 15 November 2018
SMARCA4-deficient non-small cell carcinoma of the lung is an emerging subtype of lung cancer.[1]
General
- ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
IHC
Features:[1]
- CK7 +ve.
- TTF-1 -ve.
- HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).[1]
- SMARCA4 -ve.
See also
References
- ↑ 1.0 1.1 1.2 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
- ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.